Topline Results from PALM 007 Study of SIGA’s Tecovirimat in Treatment of Mpox Released
August 15, 2024 07:35 ET
|
SIGA Technologies Inc.
Preliminary analysis shows the study did not reach statistical significance on its primary endpoint of tecovirimat being superior to placebo in lesion resolution for all patientsResults suggest...
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2024
August 01, 2024 16:05 ET
|
SIGA Technologies Inc.
Generated Product Sales of $21 Million in the Second Quarter, and $45 Million in the Six Months Ended June 30, 2024Received $113 Million Procurement Order from U.S. Government for Oral TPOXX in...
SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results
July 25, 2024 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX®
July 19, 2024 08:00 ET
|
SIGA Technologies Inc.
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the U.S. Department of Health and Human...
SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States
June 17, 2024 16:05 ET
|
SIGA Technologies Inc.
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on global health and infectious diseases, announced today an agreement to...
SIGA Reports Financial Results for Three Months Ended March 31, 2024
May 07, 2024 16:05 ET
|
SIGA Technologies Inc.
Generated Product Sales of $24 Million and Pre-tax Operating Income of $11 MillionCorporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies,...
SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results
May 01, 2024 17:00 ET
|
SIGA Technologies Inc.
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®
April 01, 2024 16:05 ET
|
SIGA Technologies Inc.
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that...
SIGA Names Larry Miller General Counsel
March 25, 2024 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the...
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023
March 12, 2024 16:05 ET
|
SIGA Technologies Inc.
• Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference...